1. Introduction {#sec0001}
===============

The novel \"SARS-CoV-2\" or \"2019-nCoV\" coronavirus disease (COVID-19) identified in Wuhan is not the first coronavirus to have quickly spread and caused havoc in the 21^st^ century. The SARS-CoV identified in Canton (Severe Acute Respiratory Syndrome, SARS hereby), became the first zoonosis of this century (2002) ([@bib0017]), followed by the MERS-CoV (Middle East Respiratory Syndrome MERS hereby), identified in 2012 in Saudi Arabia. These three syndromes can be transmitted by mildly ill, pre-symptomatic or asymptomatic infected individuals ([@bib0081]) and are putting healthcare systems under unprecedented pressure ([@bib0035]; [@bib0081]; [@bib0096]). Half of the general population rated the psychological impact of the COVID-19 outbreak as being moderate or severe ([@bib0091]). However, the World Health Organisation has identified health care workers (HCW) as a group at particular risk of developing a wide range of physical/mental problems as a result of working directly or indirectly with COVID-19 patients ([@bib0050]). HCW are particularly exposed to the threat of transmission ([@bib0038]) because of their frontline work with patients with high viral loads and suboptimal personal protection equipment ([@bib0022]; [@bib0026]; [@bib0068]). At the same time, severe stress, high emotional load, long working hours, concerns of being infected or infecting their relatives, lack of adequate support in the working environment and lack of effective supportive treatments can affect HCW\'s mental health ([@bib0066]; [@bib0090]).

Despite the profound impact of these syndromes on HCW\'s physical/mental health, to our knowledge, no systematic review has comprehensively appraised the burden (type and frequency) of these outcomes in the current literature. Profiling the impact of SARS/MERS/COVID-19 on the HCW\'s health is pivotal to inform detection, monitoring and preventive/treatment strategies. The current systematic review and meta-analysis provide the first quantitative evidence synthesis of the impact of SARS/MERS/COVID-19 on physical and mental health outcomes of HCW.

2. Methods {#sec0002}
==========

This study (study protocol registered on PROSPERO-CRD42020180205) was conducted in accordance with "Preferred Reporting Items for Systematic Reviews and Meta-Analyses" (PRISMA) ([@bib0067]) (eTable I) and "Meta-analyses Of Observational Studies in Epidemiology" (MOOSE) checklist ([@bib0084]) (eTable II), following "EQUATOR Reporting Guidelines" ([@bib0006]).

2.1. Search strategy and selection criteria {#sec0003}
-------------------------------------------

A systematic literature search was carried out by two independent researchers (GSP, AC) using the following keywords: "SARS" OR "COV" OR "coronavirus" OR "MERS" OR "Orthocoronavirinae" OR "Severe Acute Respiratory Syndrome" OR "Middle East Respiratory Syndrome" OR \"CoV-19" OR "SARS-CoV" OR \"SARS-CoV-2" OR \"2019 nCoV\" OR "2019nCoV" OR \"2019 novel coronavirus\" OR \"COVID 19\" OR \"new coronavirus\" OR \"novel coronavirus\" OR \"SARS CoV-2\" OR "Wuhan coronavirus" OR \"COVID 19\" OR \"2019-nCoV\" AND "professionals" OR "worker\*" OR "doctor\*" OR "nurse\*" OR "occupation\*" OR "employee\*" OR "healthcare provider\*" OR "healthcare worker\*" OR "healthcare employee\*" OR "personnel" OR "emergency worker" OR "paramedic\*". First, Web of Science database (Clarivate Analytics) was searched, incorporating the Web of Science Core Collection, the BIOSIS Citation Index, the KCI-Korean Journal Database, MEDLINE®, the Russian Science Citation Index, and the SciELO Citation Index, from inception until 15th April 2020. Second, given that this field is rapidly developing, we searched the preprint servers medRxiv, psyArXiv and bioRxiv for the terms 'coronavirus' or 'COVID-19' from 1st January 2020 until 15th April 2020. Third, we searched references from included studies and reviews that were screened during the literature search. We screened articles identified as abstracts, and after excluding those that did not meet our inclusion criteria, the full texts of the remaining articles were assessed for eligibility and decisions made about their inclusion.

2.2. Condition and individuals being studied {#sec0004}
--------------------------------------------

Inclusion criteria for the systematic review were a) individual studies with primary data (including letters, commentaries, qualitative studies and conference proceedings) or grey literature, b) focusing on HCW (including physicians, nurses, trainees and other health professionals) exposed to or infected by SARS/MERS/COVID-19 (see below), c) reporting physical or mental health outcomes, d) sample size \>5 and e) written in English. Exclusion Criteria were a) reviews, clinical cases, or study protocols, b) reporting outcomes on populations other than HCW, including the general population, c) with sample size ≤5. For the meta-analysis, additional inclusion criteria were a) reporting meta-analysable data and b) non-overlapping samples (overlap was determined by looking at the type of population and country in which the study was carried, and the study with the largest sample was then selected).

2.3. Data extraction {#sec0005}
--------------------

Two researchers (GSP, JVS) independently extracted data from all the included studies. The two databases were then cross-checked, and discrepancies were resolved through consensus under the supervision of a senior researcher (PFP). A summary of selected variables included: first author and year of publication, country, topic investigated, HCW category involved, sample size, age (mean± SD), sex (% female), physical/mental health, data source, quality assessment (see below) and key findings.

2.4. Risk of bias (quality) assessment {#sec0006}
--------------------------------------

Risk of bias was assessed using a modified version of the Mixed Methods Appraisal Tool (MMAT) as per protocol (detailed in eMethods 1). MMAT is considered the best and most comprehensive tool available for appraising multi-method studies ([@bib0011]).

2.5. Strategy for data synthesis {#sec0007}
--------------------------------

First, we provided a systematic synthesis (reported in the supplementary material) of the findings from the included studies structured around physical/mental health outcomes, and type of coronavirus syndromes (MERS vs SARS vs COVID-19). Second, we performed meta-analyses using, as primary effect size, the proportion (% and SE) of physical or mental health outcomes in HCW with a SARS/MERS/COVID-19 infection or exposed to SARS/MERS/COVID-19 (for details on the definition of the infection/exposure status see eMethods 2). The meta-analyses were split across physical and mental health outcomes---as operationalised by each individual study---and included both pooled and stratified estimates across SARS vs MERS vs COVID-19. Heterogeneity among studies was assessed using the Q statistic, with the proportion of the total variability in effect size estimates evaluated using the I² index (with an I^2^\>50% representing significant heterogeneity) ([@bib0058]). Random-effect models were employed as heterogeneity was expected to be high ([@bib0023]). Publication biases were not assessed because studies included in proportion meta-analyses are non-comparative; thus, there are no \"negative\" or \"undesirable\" results or study characteristics like significant levels that may have biased publications ([@bib0062]). We further conducted meta-analytical regression analyses (when data were available) to estimate the association between the analysed outcomes and: (i) sex, (ii) age, (iii) study quality, (iv) professional category (physicians vs nurses vs multi-professional samples) and (v) data source (self-administered questionnaires/surveys vs interviews/evaluations). All analyses were conducted using Comprehensive Meta-Analysis (CMA) V3 ([@bib0013]).

3. Results {#sec0008}
==========

The literature search yielded 2,925 citations (2,923 through electronic database searching and 2 through manual search), which were screened for eligibility; 324 articles were assessed in full text, and 209 were excluded (reasons for exclusion are detailed in eTable III). The final database for the systematic included 115 studies ([Fig. 1](#fig0001){ref-type="fig"} ): 65 (56.5%) focused on SARS, 26 (22.6%) on MERS and 24 (20.9%) on COVID-19; 11 (9.6%) were qualitative studies, 3 (2.6%) non-randomised interventional studies and 101 (87.8%) quantitative studies. The full database included 60,458 HCW (35,905 SARS; 5,246 MERS; 19,307 COVID-19). The total sample size of the included studies ranged from 7 ([@bib0005]; [@bib0064]) to 10,511 ([@bib0051]) HCW (eTable IV-VI). The mean age of the sample was 36.1±7.1 years ranging from 23 ([@bib0095]) to 69.4 ([@bib0074]) years; 77.1% were female. 90 (78.3%) studies included HCW from Asia, 18 (15.7%) HCW from America, 4 (3.5%) from Europe and 3% (2.6%) from more than one continent. In 64 (55.7%) studies, HCW completed self-administered questionnaires/surveys; in 51 (44.3%) studies, HCW were evaluated or interviewed by a professional. Most studies (85; 73.9%) investigated more than one HCW category; 19 studies (16.5%) focused on nurses, 9 (7.8%) on physicians, 1 (0.9%) on medical students and 1 (0.9%) on social workers. Forty studies were included in the meta-analysis ([Fig. 1](#fig0001){ref-type="fig"}), focusing on physical health outcomes in HCW infected by SARS/MERS/COVID-19 and mental health outcomes in HCW exposed to SARS/MERS/COVID-19 (see eTables IV-VI).Fig. 1PRISMA 2009 Flow Diagram.Fig 1

3.1. Physical health outcomes in HCW with SARS/MERS/COVID-19 infection {#sec0009}
----------------------------------------------------------------------

The top 10 most frequently reported physical health symptoms in those with SARS/MERS/COVID-19 infection are displayed in [Table 1](#tbl0001){ref-type="table"} , [Fig. 2](#fig0002){ref-type="fig"} and systematically described in the eTables IV-VI. The meta-analysis revealed that 75.9% of HCW with SARS/MERS/COVID-19 infection reported fever (95%CI=65.9--83.7%, k=12, n=949), 47.9% cough (95%CI=39.2--56.8%, k=14, n=970), 43.6% myalgias (95%CI=31.9--56.0%, k=13, n=898), 42.3% chills (95%CI=20.2--67.9%, k=7, n=716), 41.2% fatigue (95%CI=18.2--68.8%, k=6, n=386), 34.6% headaches (95%CI=23.1--48.2%, k=11, n=893), 31.2% dyspnoea (95%CI=23.2--40.5%, k=12, n=1003), 25.3% sore throat (95%CI=18.8--33.2%, k=8, n=747), 22.2% nausea/vomiting (95%CI=14.9--31.8%, k=6, n=662) and 18.8% diarrhoea (95%CI=11.9--28.4%, k=9, n=824) ([Table 1](#tbl0001){ref-type="table"}, [Fig. 2](#fig0002){ref-type="fig"}). Heterogeneity was statistically significant (I^2^=70.9--95.9%) and sensitivity analyses revealed that chills, fatigue and sore throat were more frequent (p\<0.001, p\<0.001, p=0.018 respectively) in SARS (73.8%, 80.0%, 28.7% respectively) compared to MERS (30.0%, 25.6%, 24.5% respectively) and COVID-19 (4.5%, 38.0%, 20.7% respectively, [Table 1](#tbl0001){ref-type="table"}, [Fig. 2](#fig0002){ref-type="fig"}).Table 1Meta-analytical proportion of physical health outcomes in HCW with SARS/MERS/COVID-19 infection.Table 1SymptomGroupNo. of studiesSample sizeRandom effects modelz ScorePTest for HeterogeneityBetween-group heterogeneityProportion95 % CIQI^2^PQP**Chills**Any coronavirus77160.4230.2020.679−0.5730.566149.67595.991\<0.00146.067\<0.001SARS43150.7380.5600.8622.5580.01116.36381.6660.001MERS12830.3000.2490.356−4.521\<0.001\<0.001\<0.0011.000COVID-1921180.0450.0190.101−6.832\<0.0010.117\<0.0010.733**Cough**Any coronavirus149700.4790.3920.568−0.4520.65172.72082.125\<0.0012.8030.246SARS53290.3680.2340.527−1.6350.10220.76480.736\<0.001MERS43410.4870.2710.708−0.1110.91215.34080.4430.002COVID-1953000.5620.3970.7150.7320.46429.39786.393\<0.001**Diarrhoea**Any coronavirus98240.1880.1190.284−5.332\<0.00159.34086.518\<0.0014.8140.090SARS22090.2740.0830.610−1.3430.1793.89574.3260.048MERS23150.3060.1970.443−2.7240.0062.14753.4330.143COVID-1953000.1200.0540.247−4.441\<0.00120.66480.642\<0.001**Dyspnoea**Any coronavirus1210030.3120.2320.405−3.806\<0.00166.18283.379\<0.0015.1170.077SARS43130.3300.1710.542−1.5820.11419.85184.888\<0.001MERS33220.5380.2620.7930.2500.80315.30786.934\<0.001COVID-1953680.2020.1140.331−4.009\<0.00121.75381.612\<0.001**Fatigue**Any coronavirus63860.4120.1820.688−0.6090.54396.69594.829\<0.00148.167\<0.001SARS11930.8000.7380.8517.704\<0.001\<0.001\<0.0011.000MERS2510.2560.1550.393−3.3050.0010.315\<0.0010.575COVID-1931420.3800.1530.674−0.7890.43018.58289.237\<0.001**Fever**Any coronavirus129490.7590.6590.8374.595\<0.00171.01984.511\<0.0014.7160.095SARS43150.9630.7630.9953.0560.00212.16675.3410.007MERS33340.6710.3420.8891.0210.30715.71687.274\<0.001COVID-1953000.7140.5760.8202.9590.00320.44580.435\<0.001**Headaches**Any coronavirus118930.3460.2310.482−2.2110.027118.56591.566\<0.0012.9330.231SARS43130.5180.3070.7230.1600.87326.79788.805\<0.001MERS33340.2740.0770.629−1.2710.20421.75690.807\<0.001COVID-1942460.2320.0710.545−1.7040.08847.14793.637\<0.001**Myalgias**Any coronavirus138980.4360.3190.560−1.0130.311106.41588.723\<0.00140.447\<0.001SARS53290.6330.5420.7162.8260.0057.63647.6130.106MERS43410.4090.1930.667−0.6760.49923.12687.027\<0.001COVID-1942280.1780.0420.515−1.8850.05948.19893.776\<0.001**Nausea/ vomits**Any coronavirus66620.2220.1490.318−5.030\<0.00122.10577.3800.0011.8960.387SARS22070.2760.2190.341−6.198\<0.0010.282\<0.0010.595MERS23150.2830.1510.467−2.2830.0223.23469.0830.072COVID-1921400.0710.0080.428−2.2110.0275.17080.6570.023**Sore throat**Any coronavirus87470.2530.1880.332−5.539\<0.00124.03470.8740.0018.0750.018SARS22090.2870.1170.549−1.6130.1074.58478.1870.032MERS33340.2450.2020.294−8.825\<0.0010.618\<0.0010.734COVID-1932040.2070.0790.443−2.3650.01814.17585.8900.001[^1]Fig. 2Top 10 Most frequently reported physical health outcomes in HCW with SARS/MERS/COVID-19 infection.Fig 2

3.2. Mental health outcomes in HCW exposed to SARS/MERS/COVID-19 {#sec0010}
----------------------------------------------------------------

The top 10 most frequently reported symptoms in SARS/MERS/COVID-19 are displayed in [Table 2](#tbl0002){ref-type="table"} , [Fig. 3](#fig0003){ref-type="fig"} ) and systematically described in the eTables IV-VI. The meta-analysis revealed that 62.5% HCW exposed to SARS/MERS/COVID-19 reported general health concerns (95%CI=57.0--67.8%, k=2, n=2254), 43.7% fear (95%CI=33.9--54.0%, k=4, n=584), 37.9% insomnia (95%CI=30.9--45.5%, k=6, n=5067), 37.8% psychological distress (95%CI=28.4--48.2%, k=15, n=24,346), 34.4% burnout (95%CI=19.3--53.5%, k=3, n=1337), 29.0% anxiety features (95%CI=14.2--50.3%, k=6, n=9191), 26.3% depressive symptoms (95%CI=12.5--47.1%, k=8, n=9893), 20.7%, post-traumatic stress disorder (PTSD) features (95%CI=13.2--31%, k=11, n=3826), 16.1% somatisation (95%CI=0.2--96.0%, k=2, n=2184) and 14.0% stigmatisation feelings (95%CI=6.4--28.1%, k=2, n=411) ([Table 1](#tbl0001){ref-type="table"}, [Fig. 2](#fig0002){ref-type="fig"}). Heterogeneity was substantial (I^2^=70.2--99.7%) and sensitivity analyses revealed that PTSD features were more frequent (p\<0.001) in MERS (40.7%) than in SARS (16.7%) and COVID-19 (7.7%, [Table 2](#tbl0002){ref-type="table"}, [Fig. 3](#fig0003){ref-type="fig"}).Table 2Meta-analytical proportion of mental health outcomes in HCW exposed to SARS/MERS/COVID-19Table 2SymptomGroupNo. of studiesSample sizeRandom effects modelz ScorePTest for HeterogeneityBetween-group heterogeneityProportion95 % CIQI^2^PQP**Psychological distress**Any coronavirus15243460.3780.2840.482−2.2930.0222572.02799.456\<0.0011.1020.576SARS10171440.4090.2930.536−1.4060.1601358.87299.338\<0.001MERS24130.3230.2160.453−2.6380.0082.23555.2490.135COVID-19367890.2990.0890.652−1.130.258780.73399.744\<0.001**Anxiety features**Any coronavirus691910.2900.1420.503−1.9350.0531318.34699.621\<0.0010.5570.456SARS214750.4570.0510.930−0.1220.903214.08699.533\<0.001COVID-19477160.2220.1270.358−3.660\<0.001329.83999.090\<0.001**PTSD features**Any coronavirus1138260.2070.1320.310−4.851\<0.001390.3897.438\<0.00122.741\<0.001SARS725700.1670.1260.220−9.354\<0.00151.13888.267\<0.001MERS37860.4070.1990.656−0.7220.47082.56197.578\<0.001COVID-1914700.0770.0560.105−14.355\<0.001\<0.001\<0.0011.000**Depressive symptoms**Any coronavirus898930.2630.1250.471−2.2120.0271898.2799.631\<0.0011.1530.283SARS421770.3680.1260.701−0.7610.447478.47499.373\<0.001COVID-19477160.1790.0670.401−2.6590.008791.15499.621\<0.001**Insomnia**Any coronavirus650670.3790.3090.455−3.0790.002134.20196.274\<0.0010.9990.317SARS315770.2950.1070.593−1.3690.171102.89098.056\<0.001COVID-19334900.4450.3820.509−1.6850.09229.32293.179\<0.001**Burnout**Any coronavirus313370.3440.1930.535−1.610.10767.95997.0570.0000.9640.326SARS213050.3820.1950.613−1.0010.31765.95398.484\<0.001COVID-191320.2500.1300.426−2.6910.0070.0001.000\<0.001**Stigmatisation feelings**Any coronavirus24110.1400.0640.281−4.0730.0008.81688.6580.003N.a.SARS24110.1400.0640.281−4.0730.0008.81688.6580.003**Fear**Any coronavirus45840.4370.3390.540−1.1960.23211.81374.6030.0081.2170.270SARS35570.4160.3110.530−1.4460.1489.87479.7440.007MERS1270.5400.3550.7140.4150.678\<0.001\<0.0011.000**General health concern**Any coronavirus222540.6250.5700.6784.3410.0003.35170.1610.067N.a.SARS222540.6250.5700.6784.3410.0003.35170.1610.067**Somatisation**Any coronavirus221840.1610.0020.960−0.6720.502334.98199.701\<0.001N.a.SARS221840.1610.0020.960−0.6720.502334.98199.701\<0.001[^2]Fig. 3Top 10 Most frequently reported mental health outcomes in HCW exposed to SARS/MERS/COVID-19.Fig 3

3.3. Quality assessment and meta-regressions {#sec0011}
--------------------------------------------

The quality of the included studies was 3.2±0.9 and ranged from 1 to 5. This was 2.3±0.5 in non-randomised studies, 3.7±0.6 in qualitative studies and 3.2±0.9 in quantitative descriptive studies (eTables IV-VI). Female sex was associated with higher prevalence of myalgias (β=0.041, p=0.001) and sore throat (β=0.035, p=0.004) (eTable VII). Psychological distress was associated with female sex (β=0.032, p=0.002), younger age (β=-0.106, p\<0.001), and professional category (β=-2.760, p\<0.001): studies including nurses were associated to higher psychological distress than studies including only physicians (p\<0.001) or including multi-professional samples (p\<0.001) (eTable VIII). No other meta-regressions resulted significant.

4. Discussion {#sec0012}
=============

To the best of our knowledge, this is the first systematic review to have comprehensively addressed the impact of SARS/MERS/COVID-19 on both physical and mental health of HCW. With 115 individual studies and 60,458 individuals included and several outcomes investigated, this study demonstrated that SARS/MERS/COVID-19 have a substantial impact on HCW\'s physical and mental health.

This meta-analysis identified for the first time the most frequent physical health outcomes in HCW infected by SARS/MERS/COVID-19. Fever was the most frequent symptom in HCW (75.9%); it was more frequent in the general population with COVID-19 infection (meta-analyses: 85.6--88.7% ([@bib0037]; [@bib0056]; [@bib0076]; [@bib0104])) and similarly frequent in the general population with MERS infection (meta-analysis: 77% ([@bib0008])). Cough appeared slightly less frequently in HCW (47.9%) than in the general population with COVID-19 infections (meta-analyses: 57.6--68.6% ([@bib0037]; [@bib0056]; [@bib0076]; [@bib0104])). Conversely, myalgias in HCW (43.6%) were more frequent than in the general population with COVID-19 infections (meta-analyses: myalgia/fatigue=35.8% ([@bib0056]); muscle soreness=33% ([@bib0104])). Our sensitivity analyses found that chills (42.3% across all SARS/MERS/COVID-19) were more frequent in HCW with SARS (73.8%) than MERS (30.0%) and particularly COVID-19 (4.5%) infection; frequency of chills in HCW with SARS infection was comparable to the general population (SARS: 74.0--75.5% ([@bib0060]; [@bib0086])). Frequency of fatigue in HCW (41.2%) was also comparable to the general population with COVID-19 infection (meta-analyses: 42.4--46.1% ([@bib0037]; [@bib0104])). Furthermore, in the general population, fatigue appears more frequently in SARS (60-70% ([@bib0041]; [@bib0097])) than in COVID-19 (meta-analyses: 42.4--46.1% ([@bib0037]; [@bib0104])), in line with our sensitivity analyses (fatigue in HCW: SARS=80.0%, MERS=25.6%, COVID-19=38.0%). Frequency of dyspnoea in HCW (31.2%) was comparable ([@bib0037]; [@bib0056]; [@bib0076]; [@bib0104]) to the general population with COVID-19 infection (meta-analyses: 21.4--45.6% ([@bib0037]; [@bib0076]; [@bib0104])) but lower than in the general population with MERS infection (meta-analysis: 68% ([@bib0008])). Frequency of headaches (34.6%), nausea/vomiting (22.2%) and diarrhoea (18.8%) in HCW were as frequent as in the general population with COVID-19 infection (meta-analyses: headaches=8--15.4% ([@bib0076]; [@bib0104]); nausea/vomiting=3.9--10.2% ([@bib0056]; [@bib0104]); diarrhoea=4.8-12.9% ([@bib0019]; [@bib0056]; [@bib0076]; [@bib0104])). Frequency of sore throat (25.3%) was similar between HCW and the general population infected by COVID-19 (meta-analysis: 11.0--21.9% ([@bib0056]; [@bib0076])), but lower than in the general population affected with MERS (meta-analysis: 39% ([@bib0008])). However, while our sensitivity analyses found a higher prevalence of sore throat in HCW with SARS (28.7%) compared to COVID-19 infection (20.7%), this effect was not observed in the general population (SARS: 13--25% ([@bib0040]), COVID-19 11.0--21.9% ([@bib0056]; [@bib0076])).

Whether these differences are due to differential reporting of symptoms by HCW or by a specific clinical course of these syndromes remains unclear. However, since the meta-regressions revealed that findings were not affected by the type of data source, it is possible to speculate that differences in the frequency of symptoms may characterise specific clinical manifestations of SARS/MERS/COVID-19 in HCW. The repeated exposure to high viral loads from contaminated patients ([@bib0059]) can interact with high environmental stress---which is known to affect the immune system ([@bib0088])---and theoretically account for some of these findings. Overall, the impact of SARS/MERS/COVID-19 infection on the physical health of HCW is profound, to the point that it has been identified as the most common cause of death for physicians during the outbreak ([@bib0057]), particularly general practitioners and emergency department physicians ([@bib0045]).

This is also the first meta-analysis that is specifically addressing mental health outcomes in HCW exposed to SARS/MERS/COVID-19. As global public health concerns, general health concerns represent the most frequent issue in HCW (62.5% according to our results) and a main topic in the general population ([@bib0034]; [@bib0069]; [@bib0070]). In some vulnerable groups as pregnant women, general health concerns cumulate to 94.6% ([@bib0025]). General health concerns are typically high when the outbreak starts (80.3%), intensify even further over its course (up to 88.6%) and decline (75.4%) once the acute phase has resolved ([@bib0075]). During pandemics/epidemics, fear of contracting coronaviruses has often been associated with psychological distress ([@bib0080]). Accordingly, fear (43.7%) was the second most frequent mental health issue in HCW, although less common than in the general population during SARS epidemic (individual studies: 60--70% ([@bib0012]; [@bib0018]; [@bib0099])), possibly because of higher health literacy in HCW ([@bib0003]). While the frequency of psychological distress in HCW (37.8%) was similar to that observed in the general population (SARS:39% ([@bib0024])), our meta-regression analyses found that psychological distress was particularly common in HCW subgroups (see below). Frequency of poor sleep during a COVID-19 outbreak was 18.2% in the general population ([@bib0039]), about half of what we observed in HCW (37.9%). This may be due to long shifts and working hours that typically characterise HCW\'s clinical duties during epidemics/pandemics ([@bib0072]). A frequently associated feature was burnout---already high in ordinary times for HCW ([@bib0001])---which peaked to 34.4% in HCW exposed to SARS/MERS/COVID-19; burnout is reported to be particularly high in nurses working long hours with MERS patients ([@bib0048]). Level of burnout is hardly ever reported or evaluated in the general population, but it has been related to physical distance from the epicentre of pandemic/epidemic outbreaks, with an inverted U-shaped relationship ([@bib0102]). Our meta-analysis also showed a higher frequency of anxiety (29.0%) and depressive (26.3%) features in HCW compared to the general population with SARS/MERS infection (meta-analyses: depression=15% ([@bib0077]); anxiety disorders=14.8% ([@bib0077])), although the current meta-analysis was not restricted to categorical diagnoses. Furthermore, the SARS outbreak has resulted in historically high suicide rates in the general population ([@bib0020]; [@bib0100]); suicide cases related to COVID-19 have been already reported, also in HCW ([@bib0046]). However, it is not known how risk of suicide is in HCW compared to the general population.

Although the frequency of PTSD features in HCW exposed to SARS/MERS/COVID-19 appeared lower (20.7%) than in the general population with SARS/MERS infection (meta-analysis: PTSD=32.5% ([@bib0077])), PTSD symptoms usually appear months after the traumatic experience, and it may be too early in the case of COVID-19 pandemic. In fact, mental health in SARS was found to be more impaired in the phase following the acute outbreak than in the initial phase ([@bib0021]). Future research should evaluate a potential increase in PTSD symptoms in HCW exposed to COVID-19 after the present study. An alternative explanation is that HCW may have fewer risk factors for PTSD, such as a history of physical diseases or a family history of psychiatric disorders ([@bib0087]). Our sensitivity analyses showed that--- among HCW--- PTSD features were more frequent in MERS (40.7%) than in SARS (16.7%) and COVID-19 (7.7%); this could relate to the higher levels of trauma associated with the overall higher mortality rates of MERS ([@bib0002]) in the general population (MERS=35% ([@bib0098])-41% ([@bib0002]); SARS 9.6% ([@bib0098])- 21% ([@bib0015]); COVID-19 2% ([@bib0098])-5% ([@bib0056])). HCW also experience higher levels of somatisation (16.1%) than the general population (0.4%) ([@bib0103]). Finally, 14.0% of HCW reported having stigmatisation feelings, albeit less frequently than the general population (39.5%) ([@bib0024]); some HCW expressed that people avoided not only them, due to their job, but also their families ([@bib0051]).

Overall, the findings of the current study may have some clinical implications. First, they clearly confirm that HCW are as essential as a fragile population which is put under high physical and mental health burden during SARS/MERS/COVID-19. Although HCW´s dedication and commitment outweigh the risk and their willingness to fight SARS/MERS/COVID-19 ([@bib0004]; [@bib0042]; [@bib0044]), HCW recognise to be at risk, mostly because of the lack of personal protective equipment ([@bib0043]), high working pressure ([@bib0010]; [@bib0061]; [@bib0083]) and suboptimal training/confidence when working in extreme circumstances ([@bib0036]). Second, these findings inform the detection and recognition of core physical and mental health outcomes in HCW during SARS/MERS/COVID-19 epidemics/pandemics. Given the logistic challenges of conducting research during infective outbreaks, focusing on the most frequent outcomes that are reported in HCW may represent a pragmatic advantage. For example, the vast majority of HCW (77%) were females, and our meta-regressions demonstrated that female HCW were more frequently displaying myalgias and sore throat, while young HCW, females and nurses were particularly vulnerable to SARS/MERS/COVID-19-related psychological distress. These findings can be used to develop gender/age- (or professional group-) sensitive guidelines for recognising the physical and mental health burden of these syndromes. In fact, some professional bodies are already developing specific recommendations for vulnerable categories such as pregnant HCW women (who are at risk of complications themselves and their neonates ([@bib0047])), older HCW or HCW with a history of chronic diseases ([@bib0053]). While the physical health of HCW is more frequently monitored, the current findings may guide healthcare providers and policymakers to implement systematic screenings for HCW\'s mental health. Third, the current findings can be used to design or refine preventive approaches. Services for individuals at Clinical High Risk for Psychosis ([@bib0031]; [@bib0052]; [@bib0079]) may leverage our findings to refine preventive approaches. For example, there is emerging evidence that Covid-19 may increase the incidence of short-lived psychotic episodes ([@bib0007]; [@bib0089]; [@bib0105]) also termed as brief and limited intermittent psychotic symptoms ([@bib0014]; [@bib0027]; [@bib0028]; [@bib0029]; [@bib0065]; [@bib0078]). Our review found that HCW presented with full-blown disorders as acute stress disorder ([@bib0009]) or PTSD ([@bib0055]). Outside HCW, severe mental disorders have been detected after coronavirus syndromes ([@bib0077]). This evidence suggests that monitoring for emerging mental disorders should become a cornerstone of preventive care during pandemics. Preventive approaches may include education programmes targeting HCW to inform them about their risk of developing specific physical/mental health outcomes while providing direct or indirect care to SARS/MERS/COVID-19 patients. HCW may be particularly reluctant to disclose their problems ([@bib0016]; [@bib0082]) to minimise the burden on their relatives ([@bib0016]) or because they over consider themselves self-reliant ([@bib0082]). Because the current study concurrently appraises both physical and mental health outcomes, it is particularly suited to inform cross-cutting approaches such as interventions designed to enhance resilience and therefore impact both physical and mental health ([@bib0063]). It may be possible to screen those HCW at a high risk of developing psychiatric disorders using instruments that have been validated to detect emerging severe mental disorders ([@bib0031]), such as the Comprehensive Assessment of At Risk Mental States ([@bib0101]), the Structured Interview for Bipolar At Risk States ([@bib0030]) and the PredictD ([@bib0049]). New screening instruments are being validated to identify individuals with mental health concerns in the general population with specific reference to the current COVID-19 pandemic ([@bib0054]). These approaches could be extended to all categories which this review found to be impacted by SARS/MERS/COVID-19: physicians ([@bib0033]), nurses ([@bib0085]), health care assistants ([@bib0071]), students ([@bib0094]), social workers ([@bib0032]) and trainees ([@bib0073]). Fourth, the current findings can serve as real-world targets to inform the development of effective treatments for restoring the impaired physical health and mental health of HCW, which are currently limited. Globally, substantial research investments are being deployed to establish effective treatments for physical and mental health outcomes in HCW, in particular leveraging the potential of eHealth and telemedicine during epidemics/pandemics ([@bib0066]; [@bib0092]; [@bib0093]).

This study has several limitations. First, despite our comprehensive approach, there was a limited amount of evidence to provide stratified results for the proportion of stigma, general health concern and somatisation in HCW exposed to MERS or COVID-19. Also, some emerging symptoms that have only recently been detected in the general population such as anosmia were not extensively reported in HCW, thus preventing their inclusion in the current meta-analysis. Second, heterogeneity was substantial in the evaluated outcomes. We conducted meta-analytical regression analyses to evaluate the influence of several variables on our results. Third, despite our meta-regressions, we were unable to quantify the impact of ethnic, clinical and treatment factors, or healthcare system differences, which may act as confounding factors. Forth, HCW exposed to SARS/MERS/COVID-19 may also have been infected but be asymptomatic, and infection status may have gone unnoticed by researchers. Also, it may not have been possible to detect all the symptoms that appeared in HCW. These are intrinsic limitations of the underlying primary research. Fifth, we excluded studies not published in English. This may have resulted in the exclusion of some studies, particularly from Asian countries. However, we were able to detect 115 individual studies with our approach, 90 of which were conducted in Asia. Sixth, the main symptoms of SARS in general population have not been subjected to a comprehensive meta-analysis, limiting comparative analyses with our results. Finally, because of the challenges in conducting research during a pandemic, several studies had a suboptimal design; the data source was controlled in meta-regression analyses revealing no impact on the results.

5. Conclusions {#sec0013}
==============

SARS/MERS/COVID-19 have a substantial impact on the physical and mental health of HCW, which should become a priority for public health strategies.
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